Since approval of RSV vaccines and the monoclonal antibody nirsevimab, CDC and the Food and Drug Administration (FDA) have received reports of the Pfizer (Abrsyvo) or GSK (Arexvy) RSV vaccines being administered in error to young children. CDC and FDA have also received reports of the GSK RSV vaccine (Arexvy) being administered in error to pregnant people. Vaccine administration errors are known to occur and are routinely monitored through the Vaccine Adverse Event Reporting System (VAERS). As of January 17, the number of reports received by VAERS suggests that these types of errors are uncommon in young children less than two years of age (25 reports) and pregnant people (128 reports) relative to an estimated one million infants protected from RSV either through infant receipt of nirsevimab or through vaccination of pregnant people.
Learn more at Information on Respiratory Syncytial Virus (RSV) Vaccine Administration Errors in Young Children and Pregnant People.